

12. Berberich AJ, Hegele RA. Lipid effects of glucagon-like peptide 1 receptor analogs. *Curr Opin Lipidol.* 2021;32:191-199.
13. Dahl K, Brooks A, Almazedi F, et al. Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes. *Diabetes Obes Metab.* 2021;23:1594-1603.
14. Novodvorský P, Haluzík M. The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia. *Curr Atheroscler Rep.* 2022;24:13-21.
15. Mulvihill EE. Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2. *Curr Opin Lipidol.* 2018;29:95-103.
16. Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. *Cardiovasc Diabetol.* 2022;21:169.
17. Moura FA, Scirica BM, Ruff CT. Tirzepatide for diabetes: on track to SURPASS current therapy. *Nat Med.* 2022;28:450-451.
18. <https://clinicaltrials.gov/ct2/show/NCT04255433>.
19. Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. *Nat Med.* 2022;28:591-598.
20. Wilson JM, Nikoienjad A, Robins DA, et al. The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. *Diabetes Obes Metab.* 2020;22:2451-2459.
21. Várkonyi TT, Pósa A, Pávó N, et al. Perspectives on weight control in diabetes - Tirzepatide. *Diabetes Res Clin Pract.* 2023;202:110770.
22. Nauck MA, Quast DR, Wefers J, et al. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. *Diabetes Obes Metab.* 2021;23(Suppl 3):5-29.
23. Wilson JM, Lin Y, Luo MJ, et al. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis. *Diabetes Obes Metab.* 2022;24:148-153.
24. Tschöp M, Nogueiras R, Ahrén B. Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy. *Diabetologia.* 2023;66:1796-1808.
25. Tan TM. Co-agonist therapeutics come of age for obesity. *Nat Rev Endocrinol.* 2023;19:66-67.
26. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. *Lancet.* 2023;402:529-544.
27. Jastreboff AM, Kaplan LM, Frias JP, et al. Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. *N Engl J Med.* 2023;389:514-526.
28. Abdelmalek MF, Suzuki A, Sanchez W, et al. A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study. *Contemp Clin Trials.* 2023; doi: 10.1016/j.cct.2023.107176.

ON-LINE KURZ

On-line kurz Kardiologie

PŘEDNÁŠKY

- **Co je u nových tabulek SCORE opravdu důležité? Modelové situace v ordinaci a jak je řešit** – MUDr. Jaromír Ožana, MUDr. Michal Mačák
- **Speciality v léčbě hypertenze** – doc. MUDr. Ondřej Petrák, Ph.D.
- **Aktuality a praktické tipy v léčbě dyslipidemie** – MUDr. Eva Tůmová, Ph.D.
- **Co (ne)budeme potřebovat od biochemické laboratoře pro stanovení kardiovaskulárního rizika?** – prof. MUDr. Michal Vrablík, Ph.D.

ODBOBNÝ GARANT:

prof. MUDr. Michal Vrablík, Ph.D.
III. interní klinika 1. LF UK a VFN v Praze

POŘADATEL: SOLEN, s. r. o.

POČET
KREDITŮ **2**

Registrace
ZDARMA

TERMÍN
září 2023
až srpen 2024
dostupný na
online.solen.cz

PARTNER

SERVIER
moved by you

